Resection of primary central nervous system lymphoma: impact of patient selection on overall survival

被引:25
|
作者
Schellekes, Nadav [1 ,2 ]
Barbotti, Arianna [3 ]
Abramov, Yael [1 ,2 ]
Sitt, Razi [1 ,2 ]
Di Meco, Francesco [3 ]
Ram, Zvi [1 ,2 ]
Grossman, Rachel [1 ,2 ]
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Neurosurg, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Fdn IRCCS Ist Neurol C Besta, Dept Neurosurg, Milan, Italy
关键词
primary central nervous system lymphoma; PCNSL; surgery; resection; survival; oncology; PRIMARY CNS LYMPHOMA; SURGERY;
D O I
10.3171/2020.9.JNS201980
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE Primary central nervous system lymphoma (PCNSL) is a rare CNS tumor with a poor prognosis. It is usually diagnosed by needle biopsy and treated mainly with high-dose chemotherapy. Resection is currently not considered a standard treatment option. A possible prolonged survival after resection of PCNSL lesions in selected patients has been suggested, but selection criteria for surgery, especially for solitary lesions, have never been established. METHODS The authors retrospectively searched their patient database for records of adult patients (>= 18 years) who were diagnosed and treated for a solitary PCNSL between 2005 and 2019. Patients were divided into groups according to whether they underwent resection or needle biopsy. Statistical analyses were performed in an attempt to identify variables affecting outcome and possible survival advantage and to characterize subgroups of patients who would benefit from resection of their tumor compared with undergoing biopsy only. RESULTS A total of 113 patients with a solitary lesion of PCNSL were identified; 36 patients underwent resection, and 77 had a diagnostic stereotactic biopsy only. The statically significant preoperative risk factors included age >= 70 years (adjusted HR 9.61, 95% CI 2.42-38.11; p = 0.001), deep-seated lesions (adjusted HR 3.33, 95% CI 1.13-9.84; p = 0.030), and occipital location (adjusted HR 4.26, 95% CI 1.08-16.78; p = 0.039). Having a postoperative Karnofsky Performance Scale (KPS) score < 80 (adjusted HR 3.21, 95% CI 1.05-9.77; p = 0.040) and surgical site infection (adjusted HR 4.27, 95% CI 1.18-15.47; p = 0.027) were significant postoperative risk factors after the adjustment and selection by means of other possible risk factors. In a subgroup analysis, patients younger than 70 years who underwent resection had a non-significant trend toward longer survival than those who underwent needle biopsy (median survival 35.0 months vs 15.2 months, p = 0.149). However, patients with a superficial tumor who underwent resection had significantly longer survival times than those who underwent needle biopsy (median survival 34.3 months vs 8.9 months, p = 0.014). Patients younger than 70 years who had a superficial tumor and underwent resection had significantly prolonged survival, with a median survival of 35.0 months compared with 8.9 months in patients from the same group who underwent needle biopsy (p = 0.007). CONCLUSIONS Specific subgroups of patients with a solitary PCNSL lesion might gain a survival benefit from resection compared with undergoing only a diagnostic biopsy.
引用
收藏
页码:1016 / 1025
页数:10
相关论文
共 50 条
  • [41] Primary central nervous system lymphoma
    Mohile, Nimish A.
    Abrey, Lauren E.
    SEMINARS IN RADIATION ONCOLOGY, 2007, 17 (03) : 223 - 229
  • [42] Primary Central Nervous System Lymphoma
    Manmeet S. Ahluwalia
    David M. Peereboom
    Current Treatment Options in Neurology, 2010, 12 : 347 - 359
  • [43] Primary central nervous system lymphoma
    Gelabert-Gonzalez, M.
    Castro Bouzas, D.
    Serramito-Garcia, R.
    Frieiro Dantas, C.
    Aran Echabe, E.
    NEUROLOGIA, 2013, 28 (05): : 283 - 293
  • [44] Primary central nervous system lymphoma
    de Koning, Myrthe E.
    Hof, Jurrit J.
    Jansen, Casper
    Doorduijn, Jeanette K.
    Bromberg, Jacoline E. C.
    van der Meulen, Matthijs
    JOURNAL OF NEUROLOGY, 2024, 271 (05) : 2906 - 2913
  • [45] Primary central nervous system lymphoma
    Mohile, Nimish A.
    Abrey, Lauren E.
    NEUROLOGIC CLINICS, 2007, 25 (04) : 1193 - +
  • [46] PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Omuro, Antonio M.
    NEURO-ONCOLOGY, 2009, 11 (06) : 876 - 877
  • [47] Primary central nervous system lymphoma
    Del Rio, M. Sierra
    Psimaras, D.
    Dehais, C.
    Kaloshi, G.
    Hoang-Xuan, K.
    ONCOLOGIE, 2009, 11 (02) : 78 - 82
  • [48] Primary Central Nervous System Lymphoma
    Ahluwalia, Manmeet S.
    Peereboom, David M.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2010, 12 (04) : 347 - 359
  • [49] Primary Central Nervous System Lymphoma
    Loew, Sarah
    Batchelor, Tracy T.
    SEMINARS IN NEUROLOGY, 2018, 38 (01) : 86 - 94
  • [50] Primary central nervous system lymphoma
    Illerhaus, G.
    ONKOLOGIE, 2011, 34 : 95 - 95